布比卡因与脂质体布比卡因在微创肺叶切除术中的随机试验
这项单盲随机研究比较了布比卡因与脂质体布比卡因(LipoB)局部浸润在未使用过麻醉性镇痛药的早期肺癌微创肺叶切除术患者中的效果。共入组50例患者(布比卡因组24例,LipoB组26例),两组在术后疼痛评分、住院阿片类药物用量、胸管留置时间、住院时长及远期阿片类药物使用方面均无显著差异,但LipoB组药房成本更高。
要点
- 布比卡因组与LipoB组住院期间吗啡当量用量分别为42.7 mg与48 mg(P=0.714),无显著差异。
- 布比卡因组与LipoB组中位疼痛评分分别为5.2与4.75(P=0.602),无显著差异。
- LipoB组药房成本高于布比卡因组(1052美元 vs 596美元,P=0.0001)。
核心结论
- 在未使用过麻醉性镇痛药的微创肺叶切除术患者中,布比卡因与LipoB在短期麻醉性镇痛药使用、术后疼痛评分、住院时长及长期麻醉性镇痛药使用方面相似。
研究设计与样本
- 单盲随机研究,入组50例无既往肺部手术史、因早期肺癌接受微创肺叶切除术(机器人或胸腔镜)的成人患者,随机分配至布比卡因组(含肾上腺素0.25%,1:200 000)24例或LipoB 1.3%组26例。
主要发现
- 布比卡因组与LipoB组手术时长分别为105分钟与137分钟(P=0.152),胸管留置时间分别为49小时与55小时(P=0.126),住院时长分别为2.45天与3.28天(P=0.326),均无显著差异。
- 布比卡因组与LipoB组住院期间吗啡当量分别为42.7 mg与48 mg(P=0.714),中位疼痛评分分别为5.2与4.75(P=0.602)。
- 术后2至4周麻醉性镇痛药使用率布比卡因组为57.1%(12/21)vs LipoB组54.5%(12/22)(P=1.00),术后6个月分别为5.9%(1/17)vs 9.5%(2/21)(P=1.00)。
- 总成本布比卡因组为20 252美元 vs LipoB组22 775美元(P=0.225),但LipoB组药房成本更高(1052美元 vs 596美元,P=0.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of this single-blind randomized study is to compare local infiltration of bupivacaine or liposomal bupivacaine (LipoB) in narcotic naïve patients undergoing minimally invasive lobectomy for early stage lung cancer. METHODS: Adult patients without previous lung surgery undergoing minimally invasive lobectomy (robotic or thoracoscopic) for early stage lung cancer were randomly assigned to bupivacaine (with epinephrine 0.25%, 1:200 000) or LipoB 1.3%. Pain level was documented using the visual analog scale and morphine equivalents for narcotic pain medications. Inhospital treatment cost and pharmacy cost were compared. RESULTS: The study enrolled 50 patients (bupivacaine, 24; LipoB, 26). The mean age of patients was 66 years, 94% were non-Hispanic white, and 48% were male. There was no difference in baseline characteristics and comorbidities. Duration of surgery (105 vs 137 minutes, P = .152), chest tube duration (49 vs 55 hours, P = .126), and length of stay (2.45 vs 3.28 days, P = .326) were similar between treatments. Inhospital morphine equivalents were 42.7 mg vs 48 mg (P = .714), and the median pain score was 5.2 vs 4.75 (P = .602) for bupivacaine vs LipoB, respectively. There was no difference in narcotic use at 2 to 4 weeks (57.1% [12 of 21] vs 54.5% [12 of 22], P = 1.00), and at 6 months (5.9% [1 of 17] vs 9.5% [2 of 21], P = 1.00) after surgery. The overall cost ($20 252 vs $22 775, P = .225) was similar; however, pharmacy cost for LipoB was higher ($1052 vs $596, P = .0001). CONCLUSIONS: In narcotic naïve patients undergoing minimally invasive lobectomy, short-term narcotic use, postoperative pain scores, length of stay, and long-term narcotic use were similar between bupivacaine and LipoB.
引用
- Thuppal S, Sleiman A, Chawla K, et al. Randomized Trial of Bupivacaine Versus Liposomal Bupivacaine in Minimally Invasive Lobectomy. Ann Thorac Surg. 2022. PMID: 35331700. doi:10.1016/j.athoracsur.2022.02.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。